Figure 5.
BR-BCSC signature strongly predicts a poor overall survival in lymph node-positive breast cancer patients. Kaplan–Meier analysis of DFS (A) and OS (B) using the BR-BCSC signature in both lymph node-positive and lymph node-negative breast cancer. LN-positive cases with a BR-BCSC signature were from patients who exhibited the worst DFS (59.8 ± 11.8 months vs. 79.0 ± 3.5 months in LN-positive cases with no BR-BCSC signature) and OS (60.4 ± 11.8 months vs. 86.2 ± 3.2 in LN-positive cases with no BR-BCSC signature).